American Association for Cancer Research
00085472can113336-sup-f6_178k.pdf (178.39 kB)

Supplementary Figure 6 from A Novel Tankyrase Inhibitor Decreases Canonical Wnt Signaling in Colon Carcinoma Cells and Reduces Tumor Growth in Conditional APC Mutant Mice

Download (178.39 kB)
journal contribution
posted on 2023-03-30, 21:03 authored by Jo Waaler, Ondrej Machon, Lucie Tumova, Huyen Dinh, Vladimir Korinek, Steven Ray Wilson, Jan Erik Paulsen, Nina Marie Pedersen, Tor J. Eide, Olga Machonova, Dietmar Gradl, Andrey Voronkov, Jens Peter von Kries, Stefan Krauss

PDF file - 178K, Pictures of the ileum (DMSO treated small intestine) that show delineated flat adenomas (A), with a few goblet cells (arrow)(B), a transition between normal epithelium and neoplastic glands (arrow) (C) and aberrant crypt foci in areas with no obvious adenoma formation (arrows) (D).



Increased nuclear accumulation of β-catenin, a mediator of canonical Wnt signaling, is found in numerous tumors and is frequently associated with tumor progression and metastasis. Inhibition of Wnt/β-catenin signaling therefore is an attractive strategy for anticancer drugs. In this study, we have identified a novel small molecule inhibitor of the β-catenin signaling pathway, JW55, that functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2), regulators of the β-catenin destruction complex. Inhibition of TNKS1/2 poly(ADP-ribosyl)ation activity by JW55 led to stabilization of AXIN2, a member of the β-catenin destruction complex, followed by increased degradation of β-catenin. In a dose-dependent manner, JW55 inhibited canonical Wnt signaling in colon carcinoma cells that contained mutations in either the APC (adenomatous polyposis coli) locus or in an allele of β-catenin. In addition, JW55 reduced XWnt8-induced axis duplication in Xenopus embryos and tamoxifen-induced polyposis formation in conditional APC mutant mice. Together, our findings provide a novel chemotype for targeting canonical Wnt/β-catenin signaling through inhibiting the PARP domain of TNKS1/2. Cancer Res; 72(11); 2822–32. ©2012 AACR.

Usage metrics

    Cancer Research



    Ref. manager